In particular, in non-small-cell lung cancer, the cutoff value of PD-L1 was lowered from 50% to 1%, and immune checkpoint inhibitors are now considered as the first-line treatment for advanced stage tumor with or without conventional chemotherapy [21,23,24]. Here, CD274 is linked to non-small cell lung carcinoma.